The present disclosure relates to an arylamine compound and an organic electroluminescent device. The arylamine compound has a structure represented by Formula (1), and contains N atoms rich in electrons and a number of large conjugated systems, so that the electron mobility and the transition rate can be improved. The device prepared from the arylamine compound has high electrical stability, and device efficiency and long device lifetime.

##STR00001##

The present disclosure relates to an arylamine compound and an organic electroluminescent device. The arylamine compound has a structure represented by Formula (1), and contains N atoms rich in electrons and a number of large conjugated systems, so that the electron mobility and the transition rate can be improved. The device prepared from the arylamine compound has high electrical stability, and device efficiency and long device lifetime.

##STR00001##

Various embodiments of the present disclosure are directed to compounds having Formula I, Formula II, Formula IIA, Formula III, Formula IIIA, Formula IIIB, and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases and/or treating associated diseases. In some embodiments, subject compounds are used to prepare a composition that is effective in treating neurodegenerative diseases.

Various embodiments of the present disclosure are directed to compounds having Formula I, Formula II, Formula IIA, Formula III, Formula IIIA, Formula IIIB, and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases and/or treating associated diseases. In some embodiments, subject compounds are used to prepare a composition that is effective in treating neurodegenerative diseases.

Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen oxide, a solvate, or a solvate of the pharmaceutically acceptable salt thereof. The fused ring compound of the present invention has high P2X4 antagonistic activity, excellent selectivity, low toxicity and excellent metabolic stability.

##STR00001##

Co-crystals and pharmaceutically acceptable salts and methods for the preparation of the co-crystals and the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, pharmaceutical compositions including them as well as their use as medicines and more particularly for use in the prevention and/or treatment of inflammatory diseases, diseases caused by viruses and/or cancer or dysplasia.

Co-crystals and pharmaceutically acceptable salts and methods for the preparation of the co-crystals and the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, pharmaceutical compositions including them as well as their use as medicines and more particularly for use in the prevention and/or treatment of inflammatory diseases, diseases caused by viruses and/or cancer or dysplasia.

Described are polymerizable high energy light absorbing compounds of formula I:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, and X are as described herein. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light and are suitable for incorporation in various products, such as biomedical devices and ophthalmic devices.

The present disclosure relates to a compound of Formula I, or a geometric isomer, enantiomer, diastereomer, racemate, atropisomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The present disclosure further relates to a composition comprising the compound of Formula (I). The compound and the composition described herein can be used to inhibit NADPH oxidase activity. ##STR00001##

7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).